Strategic Analysis of the Global Pharmaceutical Contract Manufacturing Industry

The global pharmaceutical contract manufacturing/contract research market is anticipated to reach USD 238.3 billion by 2025, according to a new report by Grand View Research, Inc. Impact on the volume of capacity that is required for production due to of increasing expression levels is anticipated to influence outsourcing industry. Increased cell densities as well as increase in expression of each cell has led to the steady decline in the volume requirement. The aforementioned fact provides the client with choices for in selection from several CMOs, which was not the fact earlier. 

View summary of this report, Click Here 

The focus of large pharmaceutical companies to strategically engage with a small number of preferred providers is a meaningful departure from the procurement-based outsourcing. This was one of the many approaches that the service industry had become accustomed to.

Expanding market for biosimilars and biobetters is anticipated to pronounce the demand for contract development and manufacturing support. Service providers that hold the potential of providing cost as well as quality advantages are set to make inroads and grow at tremendous pace in the forecast period.

However, as drug manufacturers are increasing the investments with respect to production capabilities. This may limit the potential growth of contract manufacturing services to traditional customers thereby hampering industrial growth.

Further Key Findings from the Report Suggest:

• Contract manufacturing services estimated to dominate the market over research services
• These services are segmented on the basis of development of different forms of formulations. Active Pharmaceutical Ingredient (API) / Bulk drugs registered the largest share of revenue.
• Pharmaceutical companies prefer the outsourcing services for API research and manufacture
• Factors supportive for this trend includes reduction in the cost of production of APIs
• Active molecules from small companies are always acquired by the big pharmaceutical companies
• The prominent entities focus on marketing rather than core competencies of production of API in order to maintain presence
• Finished dose formulations are expected to register the fastest growth in the coming years
• Contract research services for oncology dominated the market and are anticipated to maintain the dominance in the coming years
• CMOs/CDMOs with the ability to establish facilities in emerging countries are expected to drive growth
• Companies can position themselves for strong growth, given that demand is expected to expand rapidly in the coming years
• The major countries include Brazil. Russia, India, and China as the contract service sector is in its infancy in these regions
• Key players contributing in this market are AbbVie Contract Manufacturing, Catalent, Grifols International, S.A., Baxter BioPharma Solutions, Boehringer Ingelheim Biopharmaceuticals Gmbh, Dalton Pharma Services, and Patheon.
• Companies are engaged in lifecycle management of small-molecule drugs through the development of modified generics with uniquely enhanced properties

Click Here For Continue Reading : https://goo.gl/cBe2oX

Click Here For Sample Report : https://goo.gl/mYk41c

Complementary & alternative medicine market is expected to generate a revenue of USD 196.87 billion by 2025

Factors such as the increase in adoption of alternative medicine by people combined with the government initiatives of a number of key countries to enhance reach is expected to help in expansion revenue generation avenues.

Complementary and alternative forms of therapy are used in the treatment of chronic ailments, long-term pain among others and are also used for additional vitamins and other dietary supplementation of regular diet. Moreover, with considerable increase in the costs of conventional medicine and inclination towards body wellness rather than pharmaceutical cure is likely to boost the market over the forecast period. 

As of early 2016, approximately two thirds of the population in most of the developed and developing countries have reported using one or the other form of alternative or complementary form of medicine. There are certain countries that are moving towards the legalization of some alternative medicine therapies that are being backed with approved clinical data.

                                   View summary of this report, Click Here 

Further key findings from the report suggest:

• The market is driven by high adoption rates of herbal dietary supplements other wellness therapies like yoga, acupuncture
• Usage of botanicals has become the most prominent form of alternative medicine as the segment was observed to account for generation of the largest share of revenue
• Europe and the Asia Pacific regions emerge as clear hotspots for these forms of therapies and combine to generate the major share of market revenue
• Developing regions such as Latin America and Middle East Asia are set to witness considerable growth in demand over the forecast period driven by the expensive nature of conventional medicine and lack thereof is certain countries
• Some of the key players and wellness institutes active in the market are Pacific Nutritional Inc, Herb Pharm, Herbal Hills, Helio USA Inc, Deepure Plus, Nordic Naturals, Pure encapsulations, Inc., and other wellness institutes like Iyengar Yoga Institute, John Schumacher’s Unity Woods Yoga Center, Yoga Tree, The Healing Company and Quantum Touch Inc.

For More Access Click Here:  https://goo.gl/eih9RV

Reasons Why You Should Invest In Oncology Based In-vivo CRO Market

The global oncology based in-vivo CRO market is expected to reach USD 1.5 billion by 2025, according to a new report by Grand View Research, Inc. The use of Contract Research Organization (CRO) oncology services helps the manufacturers/sponsors to provide complete attention on the production capacity and at enhancing their in-house processes.

Furthermore, the pressure from the increasing competition due to patent expirations, rapid growth of generics, and introduction of biosimilar equivalents are propelling the pharmaceutical companies to take the aid of such organizations. Hence, it can be predicted that the oncology based in-vivo CRO market may witness lucrative growth over the forecast period.

Another factor propelling growth is the increasing incidence of cancer, and high failure rate of existing treatment options. According to statistics published by the World Health Organization (WHO), approximately 8.2 million deaths are recorded each year from cancer, which accounts for 13.0% deaths worldwide.

View summary of this report, Click Here 

Further key findings from the study suggest:

• Based on indication, solid tumors are expected to dominate the market as of 2016. Furthermore, it is anticipated to grow at the fastest CAGR owing to the factors such as growing incidence rate, augmenting research for tumors in organs such as breast, and liver, and technological advancement offered by key industry players.
• Solid tumors are analyzed by means of models such as xenograft, Patient Derived Xenografts (PDX), and syngeneic. The PDX models are expected to witness lucrative growth over the forecast period and capture over 40.0% of the market share by 2025.
• Geographic expansion into Asia Pacific countries by well-established players is anticipated to promote the fastest growth for the region. India is one the most lucrative country owing to presence of service tax exemption and venture capital based funding for CROs.
• Few of the industry players for the oncology based in-vivo CRO market are The Jackson Laboratory, Covance, Taconic Biosciences, Charles River Laboratory, EVOTEC, Wuxi AppTec, and ICON Plc.
• A common trend observed is the rising partnerships among CROs to offer bundle packages of services to sponsors. For instance, In May 2017, CRL International, Inc. announced their partnership with OcellO, established in Netherlands. According to this partnership, CRL would be utilizing the latter’s PDX model capabilities in order to expand their oncology based drug discovery service portfolio.

For Access Full Report Click Here :  https://goo.gl/xDBbEf

Injectable devices which enable the convenient self-injection by the patients are some of the factors expected to fuel the growth of drug and gene delivery system market

The global drug and gene delivery systems market is expected to reach USD 786.9 Billion by 2025, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Drug delivery systems are in a constant evolution along with the changing preference by the patient. For instance, initially, hormone replacement therapy was widely prescribed in the form of pills, whereas, it is now available in the form of prefilled syringes, patches, vaginal rings, gel, and sprays. The principal purpose of development of different forms of delivery systems is to increase the ease of use. Factors such as aesthetics of the delivery systems, price, and amount of API are also considered while designing the drug delivery system.

View summary of this report, Click Here 

Further key findings from the study suggest:

• The market study suggests that oral segment dominated the market in 2015
• The convenience of use and low manufacturing cost are the prime factors responsible for the dominance of the oral delivery segment
• Injectable segment is expected to show a lucrative growth rate owing to the introduction of technically advanced injecting devices that enable convenient self-injection
• North America dominated the market in 2015 and is expected to remain dominant throughout the forecast period owing to highly developed healthcare infrastructure and high healthcare spending
• Asia pacific is expected to exhibit the fastest growth rate during the forecast period owing to the factors such as rapidly developing economies, growing disposable income, and high adaption of the advanced delivery systems
• A few of the major market players in drug delivery systems space are F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson and Johnson private Ltd, Novartis AG, Becton, Dickinson and Company, and Bayer AG.
• Major market players in the gene delivery systems space are SiBiono GeneTech Co., Unique N.V., Epeius Biotechnologies Corporation, Human Stem Cells Institute, and Shanghai Sunway Biotech Co., Ltd.

For More Access Click Here: https://goo.gl/j54yEg

Rising patient pool, increasing investment by major players in the region, and rising adoption of gout therapy market

The global gout therapeutics market is expected to reach a value of USD 8.3 billion By 2025, based on a new report by Grand View Research, Inc. The gout therapeutics market is anticipated to witness significant growth during the forecast period. This can be attributed to the introduction of major urate-lowering agents, approval of effective biologics, and increasing number of patients suffering from chronic gout.

In December 2015, AstraZeneca’s product, Zurampic (lesinurad), in combination with xanthine oxidase inhibitor (XOI) received an approval from the U. S. FDA to treat gout. Later in February 2016, the European Commission approved the drug throughout the European Union (EU). Hence, introduction of urate-lowering agents is expected to drive the market.

Introduction of biologics to treat gout and increasing adoption of newer therapies further help propel the industry. For instance, in March 2013, Novartis received an EU approval for the product, Ilaris, for use in the treatment of patients suffering from gouty arthritis.

                                                 View summary of this report, Click Here 

Further key findings from the study suggest:

• Nonsteroidal Anti-inflammatory Agents (NSAIDs) accounted for the highest share of the market in 2015, which can be credited to highest penetration, higher demand due to low cost, and efficient pain relief.
• Urate-lowering agents segment is expected to grow at the highest rate over the coming years. Expected entry of various new drugs, increasing adoption of drugs, and growing investment by key players for development of these agents are likely to drive the segment.
• Chronic gout dominated in 2015 and is expected to maintain its dominance during the forecast period. Approval of new drugs to treat chronic gout and long-term expenditure for treatment are the key factors responsible to propel the industry.
• NSAIDs, colchicine, and corticosteroids are majorly used to treat acute gout, and urate-lowering agents are utilized in chronic gout treatment in combination with NSAIDs or Colchicine.
• Geographically, North America dominated the overall industry in 2015. This is attributed to higher adoption of the newer & expensive treatments and rising awareness about arthritic conditions.
• Asia Pacific is expected to witness highest growth during the forecast period due to growing awareness and increasing healthcare expenditure. Furthermore, growing investment in the region by key players is likely to boost the regional growth.
• Some of the key players are Takeda Pharmaceutical Company Ltd.; Novartis AG; Savient Pharmaceuticals; AstraZeneca plc; GlaxoSmithKline plc; Merck& Co. Inc.; Teijin Pharma Ltd.; and Regeneron Pharmaceuticals.

Click Here For Access Full Report : https://goo.gl/yQ4RBJ

Hepatitis Hherapeutics Market Growth Is Expected To Reach USD 25.8 Billion By 2025

The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs, increase in global geriatric population, and improvement in access to hepatitis medicines.

Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.The population at a greater risk of hepatitis include people with HIV infection & HCV-infected sexual partners, who inject drugs & use intranasal drugs, recipients of infected blood products, and other population groups who live in unhygienic conditions.

According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. Various government and private agencies are actively involved in the vaccination drive to prevent hepatitis. Hepatitis C leads to more serious complications compared to hepatitis A and B. As per WHO estimates, nearly 150 million are impacted by hepatitis C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

View summary of this report, Click Here 

Further Key Findings From the Report Suggest:

• Due to very high prevalence of target disease coupled with subsequent increase in the treatment rate Hepatitis C accounted for the majority market share of 75.6% in 2016
• In 2016, North America held the largest share of nearly 42.9%. The key factors attributed to the regions high share include high patient awareness levels and the presence of advanced healthcare infrastructure. 
• Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period. High economic development coupled with rapidly increasing healthcare expenditure are amongst key factors attributing to the regions high growth rate.
• Key players include Gilead, Merck & Co. Inc., Johnson & Johnson, Bristol-Myers Squibb Company, and AbbVie Inc.

Click Here For Access Full Report : https://goo.gl/GC3LgV

Nanomedicine Market Worth Is Anticipated To Reach USD 350.8 Billion By 2025

Development of novel nanotechnology-based drugs and therapies is driven by the need to develop therapies that have fewer side effects and that are more cost-effective than traditional therapies, in particular for cancer.

Application of nanotechnology-based contrast reagents for diagnosis and monitoring of the effects of drugs on an unprecedented short timescale is also attributive drive growth in the coming years. Additionally, demand for biodegradable implants with longer lifetimes that enable tissue restoration is anticipated to influence demand.

As per the WHO factsheet, cancer is found to be one of the major causes of mortality and morbidity worldwide, with approximately 14 million new cases in 2012 and 8.2 million cancer-related deaths. Thus, demand for nanomedicine in order to curb such high incidence rate is expected to boost market progress during the forecast period.

Solutions such as nanoformulations with triggered release for tailor-made pharmacokinetics, nanoparticles for local control of tumor in combination with radiotherapy, and functionalized nanoparticles for targeted in-vivo activation of stem cell production are anticipated to drive R&D, consequently resulting in revenue generation in the coming years.

Biopharmaceutical and medical devices companies are actively engaged in development of novel products as demonstrated by the increasingly growing partnerships between leading enterprises and nanomedicine startups. For instance, in November 2015, Ablynx and Novo Nordisk signed a global collaboration and a licensing agreement for development and discovery of innovative drugs with multi-specific nanobodies. This strategic partnership is anticipated to rise the net annual sales of the products uplifting the market growth.

However, in contrary with the applications of nanotechnology, the entire process of lab to market approval is a tedious and expensive one with stringent regulatory evaluation involved thereby leading investors to remain hesitant for investments.

View summary of this report, Click Here 

Further key findings from the report suggest:

• Therapeutics accounted for the largest share of market revenue in 2016 owing to presence of nanoemulsions, nanoformulations, or nanodevices
• These devices possess the ability to cross biological barriers. Moreover, presence of drugs such as Doxil, Abraxane, and Emend is attributive for higher revenue generation
• Presence of substantial number of products manufactured through the use of microbial sources can be attributed for the largest share
• In-vitro diagnostics is expected to witness lucrative progress as a result of R&D carried out in this segment
• Introduction of nano-enabled biomarkers, vectors and contrast agents with high-specificity and sensitivity are attributive for projected progress
• Clinical cardiology is expected to witness the fastest growth through to 2025 owing to development in nano-functionalization and modification of surfaces for increased biocompatibility of implants in treatment of late thrombosis
• Moreover, an abundance of research publications and patent filings from European region with a share of about 25% in nanomedicine-related publications is supportive for revenue generation from European economies
• Asia Pacific is estimated to witness the fastest growth over the forecast period
• Factors responsible include government and regulatory authorities that have implemented a framework to encourage R&D collaborations and framework extension.
• Key players operating in this industry include Pfizer Inc., Ablynx NV, Nanotherapeutics Inc., Nanoviricides Inc., Abraxis Inc., Arrowhead Research Inc., Celgene Corporation, Bio-Gate AG, and Merck
• Active expansion strategies are undertaken by a number of the major market entities in order to strengthen their position

• North America dominated the industry in 2016, accounting for a 42% of total revenue
• Presence of key participants operating in the region are involved in collaborative activities are attributive for the largest share of North America in sector revenue

Click Here For Access Full Report : https://goo.gl/j4GPQV

Nanoparticles - Metal & Metal Oxides Market Growth In Healthcare Is Anticipated To Reach USD 80.74 Billion By 2025

Several nanotechnologies based medicines have been put forward for approval by the FDA which is anticipated to propel growth.

Success of nanomedicine has prompted the development of enhanced nanomaterials for clinical applications with particular emphasis in therapy and diagnostics. This has resulted into the significant production of metal oxide particles that hold potential utility in human medicine.

Remarkable evolution has been made in nanoparticle based medicines for theranostic applications in disease management. Diverse metals have been used for development of medicines with a promise to optimize the efficacy of nanomedicines and to improve the current standard of medical and clinical practices.

These particles are recognized to have major applications in drug delivery, diagnostic products, biomarker discovery, and product packaging. Widespread application spectrum of these particles in maintaining human health is expected to dramatically impact the progress of this market in the coming years.

Moreover, metal oxides are observed to have significant role in cancer treatment. Nanoparticle-augmented systems enable high-concentration targeted drug delivery to cancer cells, which in turn, is expected to enhance the usage rate of metal nanoparticles for cancer treatment. Development of drug delivery strategies using nanoparticle approaches are expected to bring about changes effective for cancer treatment.

However, prolonged exposure of nanoparticles adversely affects the human health as well environment thereby restraining their adoption rate. These products are involved in autophagy, oxidative stress, lysosome dysfunction, and the activation of certain signaling pathways, thereby exhibiting toxicity for human health.

View summary of this report, Click Here 

Further key findings from the report suggest:

• Presence of untapped potential in alumina and alumina oxide particles is anticipated to create immense opportunities
• Aluminum oxide in combination with polymeric membranes is studied for enhancement of drug delivery owing to its high porosity property displayed in the membranes
• This enhanced efficacy of the membrane performance by the addition of alumina nanoparticles to polymeric membranes is projected to increase its adoption
• Approval of various nanoparticle composition and surface properties for clinical diagnostics and treatment of viral infections is anticipated drive market demand
• In-vivo imaging dominated the market with respect to revenue share
• Use of antibody conjugated to Au nanorods Raman spectrum with polarized, sharpened, and enhanced results can be attributed for larger revenue share
• Oncology dominated over a decade and is projected to sustain its share over the forecast period.
• Rising incidence of cancer and other chronic multi-drug resistant diseases pronounces the demand for these particles.
• Aforementioned factor is anticipated to drive targeted delivery with fastest YoY growth
• Asia Pacific is projected to showcase lucrative progress in the coming years
• Key countries in the region are working to enhance the patient’s reach to nanotechnology-based solutions
• Moreover, continuous support from the government bodies pertaining to initiation of new projects is expected to play crucial role for projected CAGR
• Key players contributing in this market are Pfizer Inc., Brigham Women's Hospital (BWH), Immunolight LLC, nanoComposix, Nanobiotix, Nanospectra Biosciences, Inc, Merck KGaA, and AstraZeneca
• These participants are investing in development of the product portfolio that can target the chronic disorders
• Arrowhead Pharmaceuticals, Cytimmune Sciences, Inc, Nanobiotix, Celgene Corporation, Siteman Center of Cancer Nanotechnology Excellence (Washington University CCNE), and BIND Biosciences are few companies that have products in the pipeline phase.

Click Here For Access Full Report : https://goo.gl/Qp2c6R

Pharmaceutical Filtration Market Growth Is Expected To Reach USD 37.3 Billion By The Year 2025

The global pharmaceutical filtration market is expected to reach USD 37.3 billion by the year 2025 growing at a CAGR of 12.1%, according to a new report by Grand View Research, Inc. The growing expansion of the biopharmaceutical industry have resulted in enormous growth of the market with new and more enhanced technologies being used to cater to the need of drug manufacturers. Increasing demand for therapeutic biopharmaceuticals such as antibodies,hormones, and vaccines is a major factor that drives growth of the market during forecast period. Thus, many pharmaceuticals and biotechnology companies have begun to focus on the development of advanced biologics for the treatment of severe chronic diseases including cancer, heart disease, and rheumatic arthritis. 

Increasing investment in the R&D by pharmaceutical and biotechnology companies is another major factor supporting the growth of the sector. Technological advancements in filtration products is also expected to propel their adoption in manufacturing and research of biopharmaceuticals and other drugs. The technological advanced filters including membrane, pre-filters & depth media, and cartridges & capsules filters provide high reliability and efficiency during drug manufacturing process.

View summary of this report, Click Here 

Further Key Findings From The Report Suggest:

• Microfiltration is the fastest growing technique amongst others owing to its large application in generic and biopharmaceutical drug productions
• Final product processing was the largest revenue-grossing as well as fastest growing segment of the pharmaceutical filtration market, due to increase in number of companies engaged in pharmaceuticals and biologics production
• Membrane filters held the largest revenue share in the overall sector, which is attributed by its high usage in production, research, environmental testing, and other applications in the pharmaceutical industry
• MCE membrane filters accounted for the largest share in the membrane filters segment, due to its product advancement
• The manufacturing scale dominated the market in terms of revenue in 2016 owing to the increasing production of generic drugs and biopharmaceutical products
• North America is the leading regional sector, which is accounted for the largest revenue share of the overall market in 2016, because of the presence of large number of pharmaceutical, biopharmaceutical, and biotechnology companies in this region
• The Asia Pacific region is expected to grow at a highest CAGR during the forecast period due to escalating presence of drug manufacturers in the developing countries such as China and India
• Some of the major players include Eaton Corporation Plc; GE Healthcare, Parker Hannifin Corporation; Merck KGaA; Danaher Corporation, 3M; Amazon Filters Ltd.; Sartorius Stedim Biotech S.A.; Graver Technologies, LLC; and Meissner Filtration Products, Inc.  

Click Here For Access Full Report: https://goo.gl/lmXr7c

Protein Expression Market Growth Is Expected To Reach USD 3.0 Billion By The Year 2025

The global protein expression market is expected to reach USD 3.0 billion by the year 2025 growing at a CAGR of 10.4%, according to a new report by Grand View Research, Inc. The growing demand for biologics and expansion of the biopharmaceutical industry have resulted in massive growth of the protein expression market. Rising demand for therapeutic proteins such as insulin, hormones, monoclonal antibodies,and vaccines is a major factor that propels growth of the market during forecast period. Thus, many biotechnology and pharmaceuticals companies have begun to concentrate on the development and manufacturing of advanced therapeutic proteins for the treatment of severe chronic diseases such as cancer, hemophilia, infectious diseases, anemia, and multiple sclerosis.

Increasing investment in the R&D, by biotechnology and pharmaceutical companies, is another major factor supporting the sector growth. The availability of new and advanced technologies to cater the needs of drugs & biologics product manufacturers boosts the adoption of protein expression products for research and manufacturing applications. In addition, several pharmaceutical and biotechnology manufacturers are undergoing collaborations and partnerships to achieve leadership in the sector. For instance, in December 2016, Takara Bio, Inc. signed a merger agreement with Rubicon Genomics, Inc. to strengthen its genomics business.

View summary of this report, Click Here 

Further Key Findings From The Report Suggest:

• Prokaryotic expression systems segment was the largest revenue-generating amongst others owing to its large application in biologics and drug productions
• Mammalian cell expression systems is the fastest growing segment of the protein expression market owing to its growing demand for proteomics research and biologics manufacturing
• Reagents segment held the largest revenue share in the market, which is attributed to its repetitive purchase fortherapeutic, industrial, and research applications
• The services segment is projected to grow at highest rate due to increasing trend of outsourcing of protein expression services by research labs and drug manufacturers
• Therapeutic application segment was leading in 2016, due to high demand of therapeutic proteins for the treatment of cancer, infectious diseases, anemia, hemophilia, and multiple sclerosis
• The pharmaceutical and biotechnological companies segment dominated the sector in terms of revenue in 2016 due to rising focus on proteomics research and increasing production of biologics products
• North America was the leading regional market in 2016 and is expected to maintain its dominance during the forecast period, because of the presence of large number of biopharmaceutical and biotechnology companies in this region
• The Asia Pacific region is projected to grow at a highest CAGR during the forecast period owing to untapped opportunities in the developing countries including China and India

• Some of the major players include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Merck KGaA, New England Biolabs, Promega Corporation, Qiagen, and Takara Bio, Inc.  

Click Here For Access Full Report : https://goo.gl/wju9Jf

Antibiotics Market Growth Is Expected To Reach USD 57.0 Billion By 2024

Rising prevalence of infectious diseases especially in developing regions such as Asia Pacific and MEA is anticipated to contribute towards market growth.

More than 15.0% of the deaths, in children below the age of five, are estimated to be due to pneumonia and according to the statistics provided by the WHO about 9.2 million deaths were recorded in 2015. Similar to tuberculosis, the highest prevalence of the disease is identified to be in the South Asian and Sub-Saharan regions. Currently, the required antibiotic treatment is available only to one third of the infected population, thereby increasing the disease burden.

Government reforms specific to antibiotics such as the Generating Antibiotics Incentives Now (GAIN) Act in the U.S. are projected to help market growth over the forecast period. This further expected facilitate development of advanced drugs.

On the contrary, uncertain regulatory policies are likely to hinder the growth of this vertical impacting market growth significantly. In 2013, the U.S. FDA revised the guidance for registration trials for drugs used in the treatment of acute bacterial skin and skin structure infections. The guidance states the use of short term measures of anti-infective efficacy (percent reduction in lesion size at 48 to 72 hours) as opposed to long term measures such as resolution of infection at 10-14 days, which is termed as Test to Cure or TOC.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• Antibiotic segment including tetracyclines, imidazoles, lincosamides and monoclonal antibodies held commanding share in 2015 and are also anticipated to grow at a lucrative growth rate over the forecast period
• Development of monoclonal antibodies for antibiotic resistant microorganism is key highlight of this segment. Increasing incidences of pneumonia, blood stream infections, and urinary tract infections (UTI) are anticipated to foster the usage of carbapenems class of antibiotics.
• Cell wall synthesis inhibitors dominated the mechanism outlook in 2015. Majority of the antibiotics such as penicillins, cephalosporins and carbapenems forms the cell wall synthesis inhibitor class.
• RNA synthesis inhibitors as well as folic acid synthesis inhibitors are anticipated to witness healthy growth over the forecast period. Development of several antiviral drugs which inhibit transcription and reverse transcription process are anticipated to support the growth. Folic acid inhibitor sulfa drugs are anticipated to grow as they have wide application scope.
• Asia Pacific on account of huge population base, high prevalence of infectious diseases, regulation reforms and greater usage of generic medicine held commanding share in 2015.
• Latin America, especially Brazil with strong growth in pharmaceutical sector is also projected to exhibit remunerative growth. Outbreak of certain viruses such as Ebola in African region also contributed towards the significant growth of MEA region.
• Some of the key players in this vertical are Pfizer, Inc., Janssen Pharmaceuticals, Abbott, GlaxoSmithKline plc, Sanofi, Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company and Astellas Pharma, Inc.

Click Here For Access Full Report : https://goo.gl/7zeEFA

Genitourinary Drugs Market Is Expected To Reach USD 29.7 Billion By 2024

This sector is expected to be driven by high R&D investments undertaken by the key companies, which is expected to result in the large-scale development of new drug candidates. This is presumed to increase the influx of drugs at a rapid pace into the genitourinary drugs market hence providing efficient treatment alternatives for numerous genitourinary disorders.

In addition, growing incidence of drug recalls is fueling the high clinical urgency to develop relatively new and advanced drugs with targeted therapy mechanisms. These factors cumulatively are slated to present the vertical with considerable growth opportunities over the forecast period.

Furthermore, increasing global presence of the major market players is anticipated to raise the awareness levels pertaining to treatment alternatives for genitourinary diseases amongst the patients as well as the physicians. This is further expected to widen the genitourinary market growth potential during the forecast period. Growing generic drugs competition, rising presence of counterfeit drugs, and with several patent expirations in the horizon, the market growth is expected to slow down over the coming years.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• Prostate cancer held the largest share of the indication segment in 2015 owing to the rising global incidence of the condition. In addition, advances in proteomics technology and improved screening and diagnostic procedures are presumed to be responsible for the dominant share. 

• Other products segment captured the majority share of 44.8% in the application segment in 2015. This is attributed to the numerous products launched by the major market players, which is responsible in widening the growth platform. For instance, in January 2016, ProstaPlast presented transdermal urological plasters in Europe, which demonstrated its clinical efficacy in reducing urinary problems in majority of the patients.

• In 2015, North America dominated the global genitourinary drugs vertical with a share of over 42.6%. The dominant share is attributable to the high disease burden present in this region, thus driving the inclination of researchers and healthcare professionals toward advanced formulation technologies, which is anticipated to widen the growth scope for this sector.

• Asia Pacific is expected to witness a lucrative CAGR of over 5.6% during the forecast period. The exponential growth rate can be attributed to the rising healthcare spending and the improving infrastructure quality of clinical research and manufacturing facilities owing to the initiatives of the key vertical players.

• The prominent participants are employing new product development and collaborative strategies to capture greater market share and increase their presence in this sector. For instance, in March 2015, Novartis AG further enhanced its cancer immunotherapy research initiative through collaboration with Aduro Biotech to increase its activities toward discovery and development in next generation cancer immunotherapy.

Click Here For Access Full Report : https://goo.gl/rftIj3

•